The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
Open accessAbstract
OBJECTIVES: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata). DESIGN: Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up. SETTING: Primary care centres and university or hospital associated health centres in 24 countries and territories around the world. PARTICIPANTS: 17 622 women aged 16-26 years enrolled between December 2001 and May 2003. Major exclusion criteria were lifetime number of sexual partners (>4), history of abnormal cervical smear test results, and pregnancy. INTERVENTION: Three doses of quadrivalent HPV vaccine (for serotypes 6, 11, 16, and 18) or placebo at day 1, month 2, and month 6. MAIN OUTCOME MEASURES: Vaccine efficacy against cervical, vulvar, and vaginal intraepithelial neoplasia grade I and condyloma in a per protocol susceptible population that included subjects who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 and remained negative through month 7, and had no major protocol violations. Intention to treat, generally HPV naive, and unrestricted susceptible populations were also studied. RESULTS: In the per protocol susceptible population, vaccine efficacy against lesions related to the HPV types in the vaccine was 96% for cervical intraepithelial neoplasia grade I (95% confidence interval 91% to 98%), 100% for both vulvar and vaginal intraepithelial neoplasia grade I (95% CIs 74% to 100%, 64% to 100% respectively), and 99% for condyloma (96% to 100%). Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30% (17% to 41%), 75% (22% to 94%), and 48% (10% to 71%) for cervical, vulvar, and vaginal intraepithelial neoplasia grade I, respectively, and 83% (74% to 89%) for condyloma. CONCLUSIONS: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up. TRIAL REGISTRATIONS: NCT00092521 and NCT00092534.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology
Solomon, D., Davey, D., Kurman, R., Moriarty, A., O’Connor, D., Prey, M., Raab, S., Sherman, M., Wilbur, D., & Wright, T. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200208000-00015 · Cited by 822
Ault, K. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60852-6 · Cited by 590
Joura, E. A., Leodolter, S., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Garland, S. M., Harper, D. M., Tang, G. W., Ferris, D. G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60777-6 · Cited by 581
Clifford, G. M., Rana, R. K., Franceschi, S., Smith, J. S., Gough, G., & Pimenta, J. M. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0812 · Cited by 533
Garland, S. M., Steben, M., Sings, H. L., James, M., Lu, S., Railkar, R., Barr, E., Haupt, R. M., & Joura, E. A. (2009) · The Journal of Infectious Diseases · doi:10.1086/597071 · Cited by 532
Herrero, R., Castle, P. E., Schiffman, M., Bratti, M. C., Hildesheim, A., Morales, J., Alfaro, M., Sherman, M. E., Wacholder, S., Chen, S., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428850 · Cited by 377
External Genital Warts: Diagnosis, Treatment, and Prevention
Wiley, D. J., Douglas, J., Beutner, K., Cox, T., Fife, K., Moscicki, A., & Fukumoto, L. (2002) · Clinical Infectious Diseases · doi:10.1086/342109 · Cited by 354
Sideri, M., Jones, R. W., Wilkinson, E. J., Preti, M., Heller, D. S., Scurry, J., Haefner, H., & Neill, S. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000201921.69949.10 · Cited by 339
Greer, C. E., Wheeler, C. M., Ladner, M. B., Beutner, K., Coyne, M. Y., Liang, H., Langenberg, A., Yen, T. S., & Ralston, R. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.8.2058-2063.1995 · Cited by 269
Kjær, S. K., Tran, T. N., Sparen, P., Tryggvadottir, L., Munk, C., Dasbach, E., Liaw, K., Nygård, J., & Nygård, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/522863 · Cited by 240
Insinga, R. P., Dasbach, E. J., & Myers, E. R. (2003) · Clinical Infectious Diseases · doi:10.1086/375074 · Cited by 216
Srodon, M., Stoler, M. H., Baber, G. B., & Kurman, R. J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213291.96401.48 · Cited by 213
The FUTURE II Study Group (2007) · The Journal of Infectious Diseases · doi:10.1086/522864 · Cited by 182
Self-citationMaw, R. D., Reitano, M., & Roy, M. (1998) · International Journal of STD & AIDS · doi:10.1258/0956462981921143 · Cited by 176
Therapy for genital human papillomavirus-related disease
Lacey, C. J. N. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.10.020 · Cited by 171
Sideri, M., Jones, R. W., Wilkinson, E. J., Preti, M., Heller, D. S., Scurry, J., Haefner, H. K., & Neill, S. (2005) · PubMed · Cited by 155
The psychosocial impact of human papillomavirus infection: implications for health care providers
Clarke, P., Ebel, C., Catotti, D. N., et al. (1996) · International Journal of STD & AIDS · doi:10.1258/0956462961917618 · Cited by 150
The health care costs of cervical human papillomavirus–related disease
Insinga, R. P., Glass, A. G., & Rush, B. B. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.042 · Cited by 137
Squamous Vulvar Intraepithelial Neoplasia
Preti, M., van Seters, M., Sideri, M. G., & van Beurden, M. (2005) · Clinical Obstetrics & Gynecology · doi:10.1097/01.grf.0000181738.37911.03 · Cited by 113
Management of anogenital warts (condylomata acuminata).
von Krogh, G. (2001) · PubMed · Cited by 105
Exact power and sample size for vaccine efficacy studies
Chan, I. S. F., & Bohidar, N. R. (1998) · Communication in Statistics- Theory and Methods · doi:10.1080/03610929808832160 · Cited by 95
Human Papillomavirus Vaccines and Prevention of Cervical Cancer
Jansen, K. U., & SHAW, A. R. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103520 · Cited by 78
Coût du dépistage et de la prise en charge des lésions précancéreuses du col utérin en France
Bergeron, C., Breugelmans, J. G., Bouée, S., Lorans, C., Bénard, S., & Remy, V. F. M. (2006) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2006.09.005 · Cited by 32
Cited by
Jemal, A., Simard, E. P., Dorell, C., Noone, A.-M., Markowitz, L. E., Kohler, B., Eheman, C., Saraiya, M., Bandi, P., Saslow, D., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs491 · Cited by 993
Mehanna, H., Beech, T., Nicholson, T., El‐Hariry, I., McConkey, C., Paleri, V., & Roberts, S. (2013) · Head & Neck · doi:10.1002/hed.22015 · Cited by 883
US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Saraiya, M., Unger, E. R., Thompson, T. D., Lynch, C. F., Hernandez, B. Y., Lyu, C. W., Steinau, M., Watson, M., Wilkinson, E. J., Hopenhayn, C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv086 · Cited by 761
Arbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Epithelial Cell Responses to Infection with Human Papillomavirus
Stanley, M. A. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05028-11 · Cited by 473
Metadata
- Authors
- The FUTURE I/II Study Group
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-07-20
- Volume
- 341
- Issue
- jul20 1
- Pages
- c3493-c3493
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1876505025
- Cited by
- 415
- References
- 27
- FWCI
- 28.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.